Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HK2 | P52789 | 5/20 | 0.45 |
| ▸ | HK1 | P19367 | 4/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | PYGB | P11216 | 6/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Streptozosin SCHEMBL444089 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| Streptozosin SCHEMBL18402590 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| Streptozosin SCHEMBL13840968 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| Streptozosin SCHEMBL17327962 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| Streptozosin SCHEMBL15012795 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| Streptozosin SCHEMBL10201155 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| Streptozosin SCHEMBL17328035 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| Streptozosin SCHEMBL10262780 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| Streptozosin SCHEMBL18402588 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| Streptozosin SCHEMBL444088 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 146332 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122075693-A | Application of transcription factor CUX1 in preparation of product for preventing and treating diabetic foot ulcer | — | 2026-05-26 | — | — | CN | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| CN-122074448-A | Progressive pathological animal model for drug evaluation and construction method thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122074048-A | Methods of treating cancer | 诺华股份有限公司 | 2026-05-22 | — | — | CN | claimed |
| WO-2026107377-A1 | PHARMACOLOGICAL RE-ACTIVATION OF MUTANT PVHL | KARANICOLAS JOHN (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260139071-A1 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | JANSSEN BIOTECH INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137650-A1 | MODULATORS OF RAR RELATED ORPHAN RECEPTORS (RORs) | 11949098 CANADA INC (CA) | 2026-05-21 | — | — | US | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| WO-1991014445-A1 | HETEROVESICULAR LIPOSOMES | RESEARCH DEVELOPMENT FOUNDATION (US) | 1991-10-03 | — | — | WO | claimed |
| EP-0416286-A1 | Sulfonylhydrazines and their use as antineoplastic agents and as antitrypanosomal agents | YALE UNIVERSITY (US) | 1991-03-13 | — | — | EP | claimed |
| US-4978332-A | Reduced effect on cells distant from the site | MATRIX PHARMACEUTICAL, INC. (US) | 1990-12-18 | — | — | US | claimed |
| EP-0335966-A4 | VASOCONSTRICTIVE SUBSTANCES IN COMBINATION WITH CYTOTOXIC AGENTS. | MATRIX PHARMA INC (US) | 1990-02-20 | — | — | EP | claimed |
| EP-0335966-A1 | VASOCONSTRICTIVE SUBSTANCES IN COMBINATION WITH CYTOTOXIC AGENTS | MATRIX PHARMACEUTICALS, INC. (US) | 1989-10-11 | — | — | EP | claimed |
| WO-1989002734-A1 | VASOCONSTRICTIVE SUBSTANCES IN COMBINATION WITH CYTOTOXIC AGENTS | MATRIX PHARMACEUTICALS, INC. (US) | 1989-04-06 | — | — | WO | claimed |
| EP-0222425-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-05-20 | — | — | EP | claimed |
| EP-0218300-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-04-15 | — | — | EP | claimed |
| EP-0110955-A1 | BRAIN-SPECIFIC DRUG DELIVERY. | UNIV FLORIDA (US) | 1984-06-20 | — | — | EP | claimed |
| WO-1983003968-A1 | BRAIN-SPECIFIC DRUG DELIVERY | UNIVERSITY OF FLORIDA (US) | 1983-11-24 | — | — | WO | claimed |